TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8282360

Group type: EXPERIMENTAL
Intervention: 20 mg fosinopril plus 12.5 mg hydrochlorothiazide
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: 20 mg fosinopril
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: 12.5 mg hydrochlorothiazide
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 2662389

Group type: EXPERIMENTAL
Intervention: Sucralfate suspension 1 g in 5 ml qid
Number of subjects: 49

Group type: COMPARATOR
Intervention: Ranitidine 150 mg bid
Number of subjects: 49
Study: 29628483

Group type: EXPERIMENTAL
Intervention: Pemafibrate 0.1 mg/day
Number of subjects: 526

Group type: EXPERIMENTAL
Intervention: Pemafibrate 0.2 mg/day
Number of subjects: 526

Group type: EXPERIMENTAL
Intervention: Pemafibrate 0.4 mg/day
Number of subjects: 526

Group type: EXPERIMENTAL
Intervention: Fenofibrate 100 mg/day
Number of subjects: 526

Group type: EXPERIMENTAL
Intervention: Fenofibrate 200 mg/day
Number of subjects: 526

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 526
Study: 27886619

Group type: EXPERIMENTAL
Intervention: Alirocumab 150mg every 2 weeks (Q2W)
Number of subjects: 58
Study: 25256901

Group type: EXPERIMENTAL
Intervention: Incredible Years Parenting Programme (IYPP)
Number of subjects: 28
Study: 22766394

Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg single dose)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control (healthy controls)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control (MS patients without fatigue)
Number of subjects: 3
Study: 21901116

Group type: EXPERIMENTAL
Intervention: HealthyDiet group (whole grain and low postprandial insulin response grain products, fatty fish three times a week, and bilberries three portions per day)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Whole grain enriched diet (WGED) group
Number of subjects: 106

Group type: COMPARATOR
Intervention: Refined wheat breads (Control)
Number of subjects: 106
Study: 18331816

Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (OXC) monotherapy
Number of subjects: 147
Study: 16880102

Group type: EXPERIMENTAL
Intervention: Preoperative pulmonary hypertension (PHTN)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Pulmonary artery systolic pressure
Number of subjects: 79
Study: 12611748

Group type: EXPERIMENTAL
Intervention: HL 2 mg-3 mg/day (standard dose)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: HL 0.5 mg-0.75 mg/day (low dose)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: HL plasma levels
Number of subjects: 71
Study: 11317829

Group type: EXPERIMENTAL
Intervention: Oral gatifloxacin 400 mg once daily
Number of subjects: 17923
Study: 9174486

Group type: EXPERIMENTAL
Intervention: 1 g n-3 ethyl esters three times a day for 2 months
Number of subjects: 935

Group type: EXPERIMENTAL
Intervention: 1 g n-3 ethyl esters twice a day for 4 months
Number of subjects: 935

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 935

Group type: EXPERIMENTAL
Intervention: n-3 ethyl esters
Number of subjects: 935
Study: 7504142

Group type: EXPERIMENTAL
Intervention: xamoterol
Number of subjects: 40

Group type: COMPARATOR
Intervention: atenolol
Number of subjects: 40
Study: 31659983

Group type: COMPARATOR
Intervention: Overweight (BMI 25 ≤BMI <30)
Number of subjects: 22922

Group type: COMPARATOR
Intervention: Class I obesity (BMI 30 ≤BMI <35)
Number of subjects: 22922

Group type: EXPERIMENTAL
Intervention: Class III obesity (BMI ≥40)
Number of subjects: 22922

Group type: EXPERIMENTAL
Intervention: Class II obesity (BMI 35 ≤BMI <40)
Number of subjects: 22922

Group type: EXPERIMENTAL
Intervention: Obesity (all classes)
Number of subjects: 22922
Study: 31563388

Group type: EXPERIMENTAL
Intervention: Active tDCS treatment
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 16
Study: 29208832

Group type: EXPERIMENTAL
Intervention: AcrySof IOL
Number of subjects: 137

Group type: COMPARATOR
Intervention: Acriol EC IOL
Number of subjects: 137
Study: 25946503

Group type: EXPERIMENTAL
Intervention: Individualized auriculotherapy (G3)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Protocol auriculotherapy (G2)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Control group (G1)
Number of subjects: 175
Study: 24043277

Group type: EXPERIMENTAL
Intervention: Delivery Room (DR) intubation during/after SUPPORT trial
Number of subjects: 3527

Group type: COMPARATOR
Intervention: Delivery Room (DR) intubation at PMH
Number of subjects: 3527
Study: 21169815

Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg 12 hours before PCI, plus 40 mg preprocedure)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 19665835

Group type: EXPERIMENTAL
Intervention: Depressed patients (CESD positive)
Number of subjects: 391

Group type: COMPARATOR
Intervention: Non-depressed patients (CESD negative)
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Depressive symptoms (measured by CESD)
Number of subjects: 391
Study: 16910475

Group type: EXPERIMENTAL
Intervention: Sevoflurane with 0.6 mg x kg(‐1) Org 9426
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Propofol with 0.6 mg x kg(‐1) Org 9426
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Sevoflurane with 0.9 mg x kg(‐1) Org 9426
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Propofol with 0.9 mg x kg(‐1) Org 9426
Number of subjects: 38

Group type: COMPARATOR
Intervention: Sevoflurane (both doses)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Propofol (both doses)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 0.9 mg x kg(‐1) Org 9426
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Sevoflurane and Propofol
Number of subjects: 38
Study: 15479777

Group type: EXPERIMENTAL
Intervention: High-dose (>30 mg/kg) rectally administered acetaminophen
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 10
Study: 11320559

Group type: EXPERIMENTAL
Intervention: Electromagnetic fields exposure in locomotive drivers
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Electromagnetic fields exposure in persons working with monitors
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 48
Study: 9134651

Group type: EXPERIMENTAL
Intervention: PAI-1 activity in stroke patients (n = 245) at presentation (11.6 U/ml) and after three months (11.8 U/ml)
Number of subjects: 558

Group type: EXPERIMENTAL
Intervention: PAI-1 activity
Number of subjects: 558

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 558
Study: 8185448

Group type: EXPERIMENTAL
Intervention: Supervised training (12 weeks, 45 minutes duration, two sessions per week)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Nonexercise group (usual care program)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Supervised training
Number of subjects: 69

Group type: COMPARATOR
Intervention: Nonexercise group
Number of subjects: 69
Study: 2889501

Group type: EXPERIMENTAL
Intervention: sulphasalazine (SASP)
Number of subjects: 26

Group type: COMPARATOR
Intervention: D‐penicillamine (DPA)
Number of subjects: 26
Study: 31400231

Group type: EXPERIMENTAL
Intervention: 0.2 g/kg IgPro20
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: 0.4 g/kg IgPro20
Number of subjects: 172

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 172
Study: 29903026

Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cell transplantation (MSCT)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (traditional medication)
Number of subjects: 105
Study: 26966819

Group type: EXPERIMENTAL
Intervention: Kinesio taping (KT) during menstrual cycle
Number of subjects: 32

Group type: COMPARATOR
Intervention: No kinesio taping (No-KT) during menstrual cycle
Number of subjects: 32
Study: 24620041

Group type: EXPERIMENTAL
Intervention: L-protocol (lengthening exercises)
Number of subjects: 56

Group type: COMPARATOR
Intervention: C-protocol (conventional exercises)
Number of subjects: 56
Study: 23635343

Group type: EXPERIMENTAL
Intervention: Fall Video Analysis Questionnaire (FVAQ)
Number of subjects: 130
Study: 20723776

Group type: EXPERIMENTAL
Intervention: Eosinophil major basic protein detection in nasal mucus
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (chronic rhinosinusitis-like symptoms without mucosal thickening, functional endoscopic sinus surgery for other reasons, and patients without sinus disease)
Number of subjects: 23
Study: 18164064

Group type: COMPARATOR
Intervention: Laser Peripheral Iridotomy (LPI)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Early Phacoemulsification
Number of subjects: 62
Study: 16877898

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 14582575

Group type: EXPERIMENTAL
Intervention: Family empowerment intervention service for arrested youth
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Family-focused early-intervention, intensive case management service for youth entering a diversion program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comprehensive program of research and program development at Miami-Dade Juvenile Assessment Center
Number of subjects: 0
Study: 11049951

Group type: EXPERIMENTAL
Intervention: Peribulbar LA with balloon compression (group A)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Peribulbar LA alone (group B, control)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Subconjunctival LA (group C)
Number of subjects: 30
Study: 9054044

Group type: EXPERIMENTAL
Intervention: Obsidian
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Piracetam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reserpin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Piracetam plus Reserpin
Number of subjects: 0
Study: 1353654

Group type: EXPERIMENTAL
Intervention: CODETRON (acupuncture-like stimulation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 6515723

Group type: EXPERIMENTAL
Intervention: Check-up group (annual chest X-ray and bacteriological examination)
Number of subjects: 15000

Group type: COMPARATOR
Intervention: Discharge group (no annual check-ups, encouraged to report symptoms)
Number of subjects: 15000
Study: 30058061

Group type: EXPERIMENTAL
Intervention: Intramuscular 8mg lornoxicam (Group 1, n=27)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Intravenous 8mg lornoxicam (Group 2, n=24)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Total (both groups combined)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Comparison between Group 1 and Group 2
Number of subjects: 51
Study: 29018954

Group type: EXPERIMENTAL
Intervention: Cutaneous plantar anaesthesia (lidocaine injection at the centre of forefoot, lateral midfoot, and heel)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study: 26142713

Group type: EXPERIMENTAL
Intervention: Vibrance Kegel Device (VKD) with pelvic floor muscle exercises (PFMEs)
Number of subjects: 40

Group type: COMPARATOR
Intervention: PFMEs alone (Control)
Number of subjects: 40
Study: 24412896

Group type: EXPERIMENTAL
Intervention: Telephone counseling intervention for physical activity and diet
Number of subjects: 434
Study: 23045542

Group type: EXPERIMENTAL
Intervention: Patient Navigation (PN)
Number of subjects: 438

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 438
Study: 19398614

Group type: EXPERIMENTAL
Intervention: Immediate intervention consisting of eighteen 30‐minute lessons delivered twice weekly for 9 weeks, focusing on teaching critical emergent literacy skills within small groups.
Number of subjects: 220

Group type: COMPARATOR
Intervention: Delayed intervention (control group).
Number of subjects: 220
Study: 17559758

Group type: EXPERIMENTAL
Intervention: LNG-IUS followed by ablation (L-A)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LNG-IUS followed by hysterectomy (L-H)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thermal balloon endometrial ablation (TBEA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Microwave endometrial ablation (MEA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hysterectomy
Number of subjects: 0
Study: 14701889

Group type: EXPERIMENTAL
Intervention: Osteopathic spinal manipulation (3 sessions)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Usual GP care
Number of subjects: 201
Study: 10773176

Group type: COMPARATOR
Intervention: Placebo control group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psychotropic drugs
Number of subjects: 0
Study: 9312195

Group type: EXPERIMENTAL
Intervention: Pamidronate
Number of subjects: 27

Group type: COMPARATOR
Intervention: Calcium
Number of subjects: 27
Study: 8396177

Group type: EXPERIMENTAL
Intervention: 2% minocycline ointment
Number of subjects: 103

Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 103
Study: 2426069

Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy (COF regimen: Vincristine 1 mg, cyclophosphamide 600 mg, 5-fluorouracil 500 mg IV on days 1 and 8, with or without Pingyangmycin 10 mg IM on days 1, 3, 6, and 8)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 25
Study: 30673004

Group type: EXPERIMENTAL
Intervention: Home-based exercise therapy with a single supervised session (Group A)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Home-based exercise therapy with weekly supervision (Group B)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Comparison between Group A and Group B
Number of subjects: 30
Study: 26825650

Group type: EXPERIMENTAL
Intervention: Topical application of epidermal growth factor (EGF)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Conservative treatment (observation)
Number of subjects: 97
Study: 24738648

Group type: EXPERIMENTAL
Intervention: Thai traditional massage (TTM)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Sham ultrasound
Number of subjects: 72
Study: 22796513

Group type: EXPERIMENTAL
Intervention: New Clinical Pathway (NCP)
Number of subjects: 1570

Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 1570
Study: 20423624

Group type: EXPERIMENTAL
Intervention: Experimental group (exposed to the reminiscence program)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo-control group
Number of subjects: 90
Study: 17443645

Group type: EXPERIMENTAL
Intervention: Parenteral leuprolide
Number of subjects: 52

Group type: COMPARATOR
Intervention: Oral bicalutamide
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Both interventions (leuprolide and bicalutamide)
Number of subjects: 52
Study: 15886663

Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic calf and foot compression (IPCFC) applied for 1 hour twice daily in the sitting position, along with daily exercise.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group advised exercise alone.
Number of subjects: 30
Study: 12562884

Group type: EXPERIMENTAL
Intervention: Daily supervised brushing with fluoride toothpaste
Number of subjects: 273

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 273
Study: 11084786

Group type: EXPERIMENTAL
Intervention: Adenosine (3 mg bolus) with K(+)-enriched cardioplegia
Number of subjects: 68

Group type: COMPARATOR
Intervention: K(+)-enriched cardioplegia without adenosine
Number of subjects: 68
Study: 8804870

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg once daily
Number of subjects: 158

Group type: COMPARATOR
Intervention: Ranitidine 300 mg twice daily
Number of subjects: 158
Study: 1986632

Group type: EXPERIMENTAL
Intervention: Argon laser (group I, 10 subjects)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Microscissors (group II, 11 subjects)
Number of subjects: 21
Study: 6628792

Group type: EXPERIMENTAL
Intervention: 2.0% DNCB ointment for 2 days followed by 0.05% DNCB ointment daily (group I)
Number of subjects: 73

Group type: COMPARATOR
Intervention: 0.05% DNCB preparation only (group II)
Number of subjects: 73
Study: 29631974

Group type: EXPERIMENTAL
Intervention: Kinesiotaping (KT) plus quadriceps strengthening exercise
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo technique plus quadriceps strengthening exercise
Number of subjects: 32
Study: 30685301

Group type: EXPERIMENTAL
Intervention: Phenylephrine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Norepinephrine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Norepinephrine vs Phenylephrine
Number of subjects: 100
Study: 30384885

Group type: EXPERIMENTAL
Intervention: Control of 4 to 6 risk factors
Number of subjects: 2102

Group type: COMPARATOR
Intervention: Control of 0 to 1 risk factor
Number of subjects: 2102

Group type: EXPERIMENTAL
Intervention: Being a nonsmoker, regular physical activity, systolic blood pressure <130 mm Hg, following the American Heart Association Step 2 diet
Number of subjects: 2102
Study: 27044332

Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 250

Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 250
Study: 24990907

Group type: EXPERIMENTAL
Intervention: PCV13
Number of subjects: 0

Group type: COMPARATOR
Intervention: PCV7
Number of subjects: 0
Study: 22313275

Group type: EXPERIMENTAL
Intervention: Filtek Silorane Restorative System (FS)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Adper Scotchbond 1 XT with Filtek Z250 (XT)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Adper Scotchbond SE with Filtek Z250 (SE)
Number of subjects: 25
Study: 20464985

Group type: EXPERIMENTAL
Intervention: Intervention treatment group (systemic patient management including patient education, regular telephone interviews, physician-patient communication)
Number of subjects: 230

Group type: COMPARATOR
Intervention: General treatment group (normal clinical procedure)
Number of subjects: 230

Group type: COMPARATOR
Intervention: General treatment group
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Intervention treatment group
Number of subjects: 230
Study: 17013594

Group type: EXPERIMENTAL
Intervention: 0.1 mmol/kg Gd‐DTPA
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.2 mmol/kg Gd‐DTPA
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.3 mmol/kg Gd‐DTPA
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Image masking (subtraction of baseline images)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.1 mmol/kg, 0.2 mmol/kg, 0.3 mmol/kg Gd‐DTPA
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Increasing contrast agent dosage
Number of subjects: 60
Study: 15653005

Group type: EXPERIMENTAL
Intervention: Low-dose hormone replacement therapy with 0.3mg of conjugated equine estrogens (CE) and 2.5 mg MPA (CE + MPA)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Low-dose hormone replacement therapy with 0.3mg of conjugated equine estrogens (CE) and 100 mg natural micronized progesterone (CE + P)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (calcium-vitamin)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: CE + MPA and CE + P
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: CE + P
Number of subjects: 40
Study: 12505240

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 9790357

Group type: EXPERIMENTAL
Intervention: Valacyclovir (500 mg twice daily)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Acyclovir (400 mg 3 times daily)
Number of subjects: 20
Study: 7542336

Group type: EXPERIMENTAL
Intervention: Sublingual buprenorphine (0, 0.5, 2, 8, 16 and 32 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: p.o. methadone (3.75, 15 and 60 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: High doses of buprenorphine
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: High doses of methadone
Number of subjects: 9
Study: 2221770

Group type: EXPERIMENTAL
Intervention: Bupivacaine (0.6 ml/kg, 0.25% = 1.5 mg/kg) injected intradermally into the wound during general anaesthesia
Number of subjects: 20

Group type: COMPARATOR
Intervention: General anaesthesia only
Number of subjects: 20
Study: 6110433

Group type: EXPERIMENTAL
Intervention: Suxamethonium 1 mg kg‐1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no suxamethonium)
Number of subjects: 0
Study: 30855743

Group type: EXPERIMENTAL
Intervention: 5% fluorouracil cream
Number of subjects: 624

Group type: COMPARATOR
Intervention: 5% imiquimod cream
Number of subjects: 624

Group type: COMPARATOR
Intervention: methyl aminolevulinate photodynamic therapy (MAL‐PDT)
Number of subjects: 624

Group type: COMPARATOR
Intervention: 0.015% ingenol mebutate gel
Number of subjects: 624
Study: 28209654

Group type: EXPERIMENTAL
Intervention: CGM-only (n = 149)
Number of subjects: 226

Group type: COMPARATOR
Intervention: CGM+BGM (n = 77)
Number of subjects: 226
Study: 26111150

Group type: EXPERIMENTAL
Intervention: Ramipril (usual treatment group)
Number of subjects: 336
Study: 24453236

Group type: EXPERIMENTAL
Intervention: Experimental intervention (specific details not provided)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dog-leg design
Number of subjects: 0

Group type: COMPARATOR
Intervention: Parallel groups design
Number of subjects: 0
Study: 19040615

Group type: EXPERIMENTAL
Intervention: 30 microg of proinsulin peptide (C19-A3) administered intradermally in three equal doses at 0, 1, and 2 months
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 300 microg of proinsulin peptide (C19-A3) administered intradermally in three equal doses at 0, 1, and 2 months
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 30 microg of proinsulin peptide (C19-A3)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 36
Study: 17325084

Group type: EXPERIMENTAL
Intervention: Doxycycline treatment
Number of subjects: 61

Group type: COMPARATOR
Intervention: No doxycycline treatment (Control)
Number of subjects: 61
Study: 16518446

Group type: EXPERIMENTAL
Intervention: Videotape intervention
Number of subjects: 136

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 136
Study: 14656271

Group type: EXPERIMENTAL
Intervention: Cisplatin-paclitaxel regimen
Number of subjects: 2

Group type: COMPARATOR
Intervention: Cisplatin-cyclophosphamide regimen
Number of subjects: 2
Study: 10368990

Group type: EXPERIMENTAL
Intervention: Testicular biopsies showing complete or nearly complete tubular hyalinization
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Testicular biopsies from five patients
Number of subjects: 21
Study: 9381939

Group type: EXPERIMENTAL
Intervention: sulphurous thermal water
Number of subjects: 50

Group type: COMPARATOR
Intervention: placebo saline solution
Number of subjects: 50